CULLINAN THERAPEUTICS

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results

09 Nov 2021 05:45:00 By Nasdaq GlobeNewswire

Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer

18 Oct 2021 06:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

08 Sep 2021 15:01:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results

10 Aug 2021 05:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference

05 Aug 2021 15:05:00 By Nasdaq GlobeNewswire

Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

29 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

07 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

04 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Announces Management Transition

21 May 2021 07:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021

19 May 2021 16:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Reports First Quarter 2021 Financial Results

14 May 2021 05:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

07 Apr 2021 09:08:07 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights

30 Mar 2021 05:15:00 By Nasdaq GlobeNewswire